Updates as of June 13, 2022:
- Added information regarding reports of COVID-19 rebound after treatment with Paxlovid
Review the distribution fact sheets to learn about each COVID-19 outpatient therapeutic.
Bamlanivimab/etesevimab, cairivimab/imdevimab (REGEN-COV), and sotrovimab are NOT effective against the Omicron variant and/or the Omicron BA.2 subvariant and are not authorized for use anywhere in the United States. As such,
HHS and CDPH are not distributing these monoclonal antibody products at this time.
Anti-SARS-CoV-2 Monoclonal Antibodies
Antivirals
-
Molnupiravir Distribution Fact Sheet
-
Remdesivir (Veklury) Distribution Fact Sheet
-
Nirmatrelvir/Ritonavir (Paxlovid) Distribution Fact Sheet
-
Update on Paxlovid:
With reports of COVID-19 symptom recurrence after treatment with the oral antiviral agent, Paxlovid (nirmatrelvir/ritonavir), the Centers for Disease Control (CDC) issued a health alert on May 24th, 2022 addressing this phenomenon. Although COVID-19 rebound after treatment with Paxlovid has been described in case reports, there is currently no evidence that this rebound is the result of SARS-CoV-2 resistance to Paxlovid. Based on case reports, recurrent symptoms after treatment with Paxlovid appear to be mild. Because the goal of Paxlovid treatment is avoiding progression to severe disease, recurrent mild to moderate symptoms do not indicate treatment failure. Individuals with COVID-19 symptom recurrence show follow CDC and CDPH guidance regarding isolation of infected patients regardless of their treatment status. Paxlovid continues to be recommended for the treatment of mild to moderate COVID-19 among persons at high risk for progression to severe disease.
Originally published on January 19, 2022